Toby Maher

Toby Maher is Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles.

He has spent the last 15 years specialising in the management of all forms of pulmonary fibrosis and orphan interstitial lung diseases. He previously ran the ILD unit at Royal Brompton Hospital, London seeing more than 1500 new ILD patients per year. Since June 2020 he has been Director of ILD at Keck Medicine of USC. He remains Professor of Interstitial Lung Disease at Imperial College London and is British Lung Foundation Professor of Respiratory Medicine. His research interests include; biomarker discovery, the lung microbiome and host immune response in the pathogenesis of IPF and clinical trials in interstitial lung disease. He has been involved in >50 trials in fibrotic lung disease from phase 1b through to phase 4 and including those assessing IPF, scleroderma, rheumatoid arthritis and inflammatory myositis. Overall, he has recruited > 1000 patients into interventional studies. He has given expert opinion to FDA and EMA. He is an associate editor for American Journal of Respiratory and Critical Care Medicine and is on the Editorial Board of Lancet Respiratory Medicine. He has authored over 270 papers and book chapters on pulmonary fibrosis.